Onkologie. 2020:14(3):131-134 | DOI: 10.36290/xon.2020.026
Nivolumab in the treatment of recurrent or methastatic head and neck cancer
- Komplexní onkologické centrum, Nový Jičín
The therapeutic possibilities of recurrent or methastatic head and neck carcinomas are unfortunatelly limited. Systemic therapy is the only option in the case the patients are not candidates for locoregional treatment (chemotherapy or radiotherapy). Taxane, methotrexate or 5-fluorouracil based chemotherapy was only treatment possibility after disease progression on platine derivates with or without cetuximab. Immunotherapy has quickly established its position in the treatment algorytms of several tumor types and CheckMate 141 clinical trial has integrate nivolumab in the treatment of local recurrent or methastatic head and neck carcinomas when nivolumab has proven its benefit in the overall survival compared with standard of care at that time. Nivolumab has gained the registration and reimbusrsement from the public health care in the Czech Republic. Immunotherapy represents new treatment modality in the recurrent and methastatic head and neck carcinomas.
Keywords: immunotherapy, head and neck cancer, chemotherapy.
Published: June 2, 2020 Show citation
References
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19): 1856-67.
Go to original source... - Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018; 81: 45-51. Go to original source...
- Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019; 25(17): 5221-30. Go to original source...
- https://www.uptodate.com/contents/treatment-of-metastatic-and-recurrent-head-and-neck-cancer search=head%20and%20neck&source=search_result&selectedTitle =2~150&usage_type=default&display_rank=2#H3210750184
- Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017; 18(8): 1104-15. Go to original source...
- https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_cs.pdf
- Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019; 393(10167): 156-67. Go to original source...
- Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum - and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14): 1542-1549. Go to original source...
Go to PubMed... - Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17(7): 956-65. Go to original source...
- https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_cs.pdf